The Grand Rapids private investor group Grand Angels announced its latest funding commitments to a group of Michigan startups.
The cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
ProNai Therapeutics Inc. reported promising new results Sunday from an ongoing Phase II study of its lead drug candidate at the 55th Annual Meeting of the American Society for Hematology in New Orleans, La.
ProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells’ DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
ProNAi Therapeutics Inc., a cancer drug development company, said last week that it had concluded its initial human clinical trial of PNT2258, a new type of nucleic acid drug.
The Michigan Venture Capital Association’s programs to develop the state’s investment community are helping venture capitalists and their portfolio companies attract and retain top talent.